Prana Biotechnology Limited (NASDAQ:PRAN)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $1.02. Prana Biotechnology shares last traded at $0.95, with a volume of 16,782 shares trading hands.

The business’s fifty day simple moving average is $1.20. The company has a market cap of $8.46 million, a P/E ratio of -1.36 and a beta of 1.05.

Prana Biotechnology Company Profile (NASDAQ:PRAN)

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease.

Read More: Why do analysts give a neutral rating?

Receive News & Ratings for Prana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology and related companies with's FREE daily email newsletter.